Summary
- Innovator IBD® 50 ETF is a passively managed ETF tracking the IBD® 50 Index.
- FFTY is having such a moment this year, beating IVV and QQQ by a substantial margin. For context, 2017 was the only calendar year when this ETF beat IVV.
- It is worth exercising caution, thou…
Summary
- Innovator IBD® 50 ETF is a passively managed ETF tracking the IBD® 50 Index.
- FFTY is having such a moment this year, beating IVV and QQQ by a substantial margin. For context, 2017 was the only calendar year when this ETF beat IVV.
- It is worth exercising caution, though, as it is questionable whether outperformance is sustainable.
- Over May 2015–September 2025, FFTY’s annualized return was almost 3x lower than IVV’s, as it captured nearly 154% of its downside.
- Other disadvantages include ultrahigh turnover of 1,304%, relatively small AUM, and a net expense ratio of 0.80%.
bgsmith/iStock via Getty Images
Today, I would like to reassess the Innovator IBD® 50 ETF (NYSEARCA:FFTY), a passively managed exchange-traded fund with a concentrated portfolio and ultrahigh turnover, which I covered four times in 2022–2023, with the previous analysis
This article was written by
2.15K Followers
**Analyst’s Disclosure:**I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.